Structure-Activity Relationship

"Structure-Activity Relationship" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.

Descriptor ID	D013329
MeSH Number(s)	G02.111.830 G07.690.773.997
Concept/Terms	Structure-Activity Relationship Structure-Activity Relationship Relationship, Structure-Activity Relationships, Structure-Activity Structure Activity Relationship Structure-Activity Relationships

Below are MeSH descriptors whose meaning is more general than "Structure-Activity Relationship".

Biological Sciences [G]
Chemical Phenomena [G02]
Biochemical Phenomena [G02.111]
Structure-Activity Relationship [G02.111.830]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Structure-Activity Relationship [G07.690.773.997]

Below are MeSH descriptors whose meaning is related to "Structure-Activity Relationship".

Below are MeSH descriptors whose meaning is more specific than "Structure-Activity Relationship".

Structure-Activity Relationship
Quantitative Structure-Activity Relationship

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Structure-Activity Relationship" by people in this website by year, and whether "Structure-Activity Relationship" was a major or minor topic of these publications.

Bar chart showing 276 publications over 29 distinct years, with a maximum of 20 publications in 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	0	4	4
1993	0	4	4
1994	0	9	9
1995	0	7	7
1996	0	7	7
1998	0	4	4
1999	0	4	4
2000	0	6	6
2001	0	5	5
2002	0	20	20
2003	0	11	11
2004	1	9	10
2005	0	8	8
2006	0	13	13
2007	0	15	15
2008	0	9	9
2009	0	13	13
2010	1	10	11
2011	0	14	14
2012	0	13	13
2013	0	10	10
2014	1	9	10
2015	0	11	11
2016	0	15	15
2017	0	10	10
2018	0	10	10
2019	0	9	9
2020	0	5	5
2021	0	9	9

Below are the most recent publications written about "Structure-Activity Relationship" by people in Profiles.

Tahtouh T, Durieu E, Villiers B, Bruyère C, Nguyen TL, Fant X, Ahn KH, Khurana L, Deau E, Lindberg MF, Sévère E, Miege F, Roche D, Limanton E, L'Helgoual'ch JM, Burgy G, Guiheneuf S, Herault Y, Kendall DA, Carreaux F, Bazureau JP, Meijer L. Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors. J Med Chem. 2022 01 27; 65(2):1396-1417.

View in: PubMed
Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. J Med Chem. 2021 08 26; 64(16):11972-11989.

View in: PubMed
Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, C Lorenzi JC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Da Silva J, Poston D, Finkin S, Cho A, Cipolla M, Oliveira TY, Millard KG, Ramos V, Gazumyan A, Rutkowska M, Caskey M, Nussenzweig MC, Bjorkman PJ, Hatziioannou T, Bieniasz PD. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021 08 10; 54(8):1853-1868.e7.

View in: PubMed
Verma SK, Verma R, Kumar KSS, Banjare L, Shaik AB, Bhandare RR, Rakesh KP, Rangappa KS. A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies. Eur J Med Chem. 2021 Jul 05; 219:113442.

View in: PubMed
Kurt Yilmaz N, Schiffer CA. Introduction: Drug Resistance. Chem Rev. 2021 03 24; 121(6):3235-3237.

View in: PubMed
Lockbaum GJ, Henes M, Talledge N, Rusere LN, Kosovrasti K, Nalivaika EA, Somasundaran M, Ali A, Mansky LM, Kurt Yilmaz N, Schiffer CA. Inhibiting HTLV-1 Protease: A Viable Antiviral Target. ACS Chem Biol. 2021 03 19; 16(3):529-538.

View in: PubMed
Thada S, Horvath GL, Müller MM, Dittrich N, Conrad ML, Sur S, Hussain A, Pelka K, Gaddam SL, Latz E, Slevogt H, Schumann RR, Burkert S. Interaction of TLR4 and TLR8 in the Innate Immune Response against Mycobacterium Tuberculosis. Int J Mol Sci. 2021 Feb 04; 22(4).

View in: PubMed
Matthew AN, Leidner F, Lockbaum GJ, Henes M, Zephyr J, Hou S, Rao DN, Timm J, Rusere LN, Ragland DA, Paulsen JL, Prachanronarong K, Soumana DI, Nalivaika EA, Kurt Yilmaz N, Ali A, Schiffer CA. Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Chem Rev. 2021 03 24; 121(6):3238-3270.

View in: PubMed
Mishra K, Verma SK, Ratre P, Banjare L, Jain A, Thareja S, Jain AK. In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer. Anticancer Agents Med Chem. 2021; 21(9):1191-1199.

View in: PubMed
Verma R, Verma SK, Rakesh KP, Girish YR, Ashrafizadeh M, Sharath Kumar KS, Rangappa KS. Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation. Eur J Med Chem. 2021 Feb 15; 212:113134.

View in: PubMed

People

Explore

Similar Concepts

Top Journals